Fulgent Genetics (FLGT) Cash from Investing Activities (2015 - 2026)

Fulgent Genetics has reported Cash from Investing Activities for 12 years, with the latest figure at $50.8 million in Q2 2026.

• Quarterly Cash from Investing Activities fell 4.87% year-over-year to $50.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $92.0 million (up 46.78% YoY) and the FY2025 annual result came in at $111.4 million, up 290.86% from the prior year.
• Cash from Investing Activities grew to $50.8 million in Q2 2026 per FLGT's latest filing, from $10.9 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $53.4 million in Q2 2025 and troughed at -$213.7 million in Q2 2022.
• A 5-year average of -$6.0 million and a median of $10.0 million in 2024 frame the typical range for Cash from Investing Activities.
• The widest YoY moves for Cash from Investing Activities: up 766.42% in 2024, down 983.74% in 2024.
• Over 5 years, Cash from Investing Activities stood at -$92.6 million in 2022, then surged by 126.21% to $24.3 million in 2023, then sank by 213.12% to -$27.5 million in 2024, then jumped by 140.63% to $11.2 million in 2025, then soared by 355.45% to $50.8 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $50.8 million, $10.9 million, and $11.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.